Investigating genetic variations within a primary tumor, the differences between the primary tumor and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma (GEA), according to a recent study.

Read More

News

A recent study compared the effects of adjuvant chemotherapy and observation after preoperative chemoradiation and resection in gastroesophageal cancer, published in JAMA Oncology (online September 21, 2017; doi:10.1001/jamaoncol.2017.2805).

Read More

High expression of a specific protein is associated with an improved 5-year survival rate of almost 28% in gastric cancer, according to new research published in PLOS One (online August 30, 2017; doi:10.1371/journal.pone.0183868).

-----

Related Content

Read More

Recent research compared the efficacy of chemotherapy vs best supportive care, combination vs single-agent chemotherapy, and multiple different chemotherapy combinations in advanced gastric cancer (doi:10.1002/14651858.CD004064.pub4).

-----

Related Content

Read More

By Reuters Staff

NEW YORK (Reuters Health) - Post-treatment/preoperative tumor response, as measured on positron emission tomography (PET), does not predict outcomes in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma, according to a database review.

Read More

Research in Review

Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American Urological Association (AUA) Annual Meeting (May 12-16, 2017; Boston, MA).

-----

Related Content

Read More

Adding cetuximab to chemoradiation for squamous cell carcinoma of the anal canal is associated with lower incidence of locoregional failure but high toxicity, according to the results of a study published in the Journal of Clinical Oncology (March 2017;35[7]:718-726).

-----

Related Content

Read More

Imatinib mesylate front-line treatment of advanced or metastatic gastrointestinal stromal tumors (GISTs) leads to significant long-term survival in patients with a specific genetic mutation, according to study published in JAMA Oncology (published online February 9, 2017; doi:10.1001/jamaoncol.2016.6728).

Read More

Subscribe to Gastrointestinal Cancer